Latest News- Idiopathic Pulmonary Fibrosis (IPF) Market: Oral is expected to lead the Route Of Administration segment during 2025-2029

The Idiopathic Pulmonary Fibrosis (IPF) Market is being driven by Increasing prevalence of respiratory diseases

The Idiopathic Pulmonary Fibrosis (IPF) Market is expected to grow at a CAGR of 6.9% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 1605.5 million. The idiopathic pulmonary fibrosis (IPF) market has witnessed a surge in drug pipeline development due to the rising prevalence of this chronic and debilitating lung condition. IPF is characterized by the scarring of lung tissue, resulting in breathing difficulties and diminished lung function. Notable drugs in development include Pirfenidone (Esbriet), an approved antifibrotic agent that inhibits lung fibrosis progression. Other promising candidates, such as Nintedanib (Ofev) and Sotatercept (ACP-196), are also at advanced stages of clinical trials, demonstrating a robust pipeline for IPF treatment solutions. 

Get more information on Idiopathic Pulmonary Fibrosis (IPF) Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Route Of Administration
  • Oral
  • Parenteral
• Drug Class
  • Systemic corticosteroids
  • Immunosuppressants
  • Tyrosine kinase inhibitors
  • Anti-fibrotic agents
• Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• Geography
  • North America
    • Canada
    • Mexico
    • US
  • Europe
    • Germany
    • UK
    • France
    • Italy
  • Asia
    • China
    • Japan
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Increasing prevalence of respiratory diseases
• Growing geriatric population
• Increase in number of smokers

However, the market also witnesses some limitations, which are as follows:

• High cost of conducting clinical trials on IPF therapeutics
• Obstacles to reimbursement
• Low awareness of IPF and its treatment

Benefits of Buying Global Idiopathic Pulmonary Fibrosis (IPF) Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Idiopathic Pulmonary Fibrosis (IPF) Market Research Report

Request Free Sample

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disorder characterized by impaired lung function and respiratory difficulties. Diagnostic technologies such as high-resolution CT scans and biopsies are used for identification. Treatment options include antifibrotic agents like Pirfenidone and Nintedanib, immunosuppressants, and targeted therapies. Patients receive medical care through multidisciplinary teams in hospitals and clinics, pharmacies (hospital, retail, and online), and diagnostic services. Therapeutic approaches aim to improve patient outcomes and enhance quality of life.

Market Research Overview

The idiopathic pulmonary fibrosis (IPF) market falls under the broader global pharmaceuticals sector, encompassing entities involved in the research and development (R&D) or manufacturing of various drug categories, including generics, non-generics, and veterinary drugs. According to Technavio, the healthcare market size is determined by the consolidated revenue generated by providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors fueling the expansion of the pharmaceuticals market include the increasing aging population. By 2050, approximately one-quarter of the US population and Europe's population ratio is projected to surpass 60 years old, leading to a substantial increase in the demand for healthcare solutions, including those for IPF.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/